Bio-Safety Level 3 Core

The Ragon BSL3 core provides biosafety level-3 laboratory space, training, and consultation for academic and industrial researchers working with risk group-3 pathogens, such as M. tuberculosis, SARS-CoV-2, Chikungunya virus, West Nile virus, Powassan virus, Japanese Encephalitis virus, Dabie bandavirus, Heartland virus and Bhanja virus. 

Researchers are required to complete 30 hours of BSL3 specific training to become certified BSL3 core users. Training covers special facility containment, BSL-3 specific PPE, and safety regulations specific to risk group-3 pathogens.

Director

Amy Barczak

Scientific Director

Contact

Julie Boucau

Co-Director

Yong (Mike) Xie

Director

Services and Pricing

The Ragon BSL3 is one of the largest (2200 square feet) and most heavily used BSL3 facility in the region, with an excellent safety track record. The lab is equipped with dedicated 12-color high-speed cell sorter and microscopy equipment, as well as cell culture hoods and standard cell and molecular biology resources.

Learn More

Selected Publications

FcγR-mediated SARS-CoV-2 infection of monocytes activates inflammation

Caroline Junqueira, Ângela Crespo, Shahin Ranjbar, Luna B de Lacerda, Mercedes Lewandrowski, Jacob Ingber, Blair Parry, Sagi Ravid, Sarah Clark, Marie Rose Schrimpf, Felicia Ho, Caroline Beakes, Justin Margolin, Nicole Russell, Kyle Kays, Julie Boucau, Upasana Das Adhikari, Setu M Vora, Valerie Leger, Lee Gehrke, Lauren A Henderson, Erin Janssen, Douglas Kwon, Chris Sander, Jonathan Abraham, Marcia B Goldberg, Hao Wu, Gautam Mehta, Steven Bell, Anne E Goldfeld, Michael R Filbin, Judy Lieberman

Nature, 606(7914), 04/04/22 PubMed Read on Journal Site

Permanent, Antimicrobial Coating to Rapidly Kill and Prevent Transmission of Bacteria, Fungi, Influenza, and SARS-CoV-2

Sreyan Ghosh, Riya Mukherjee, Vinay S Mahajan, Julie Boucau, Shiv Pillai, Jayanta Haldar

ACS Appli Mater Interfaces, 14 (37), 09/21/2022 PubMed Read on Journal Site

Inhibition of major histocompatibility complex-I antigen presentation by sarbecovirus ORF7a proteins

Fengwen Zhang, Trinity M Zang, Eva M Stevenson, Xiao Lei, Dennis C Copertino, Talia M Mota, Julie Boucau, Wilfredo F Garcia-Beltran, R Brad Jones, Paul D Bieniasz

Proceedings of National Academy of Science, 119 (41) 10/11/2022 PubMed Read on Journal Site

Characterization of virologic rebound following nirmatrelvir-ritonavir treatment for COVID-19

Julie Boucau, Rockib Uddin, Caitlin Marino, James Regan, James P Flynn, Manish C Choudhary, Geoffrey Chen, Ashley M Stuckwisch, Josh Mathews, May Y Liew, Arshdeep Singh, Zahra Reynolds, Surabhi L Iyer, Grace C Chamberlin, Tammy D Vyas, Jatin M Vyas, Sarah E Turbett, Jonathan Z Li, Jacob E Lemieux, Amy K Barczak, Mark J Siedner

Clinical Infectious Diseases 2022 Jun 23, ciac512 PubMed Read on Journal Site

Duration of Shedding of Culturable Virus in SARS-CoV-2 Omicron (BA.1) Infection

Julie Boucau, Caitlin Marino, James Regan, Rockib Uddin, Manish C Choudhary, James P Flynn, Geoffrey Chen, Ashley M Stuckwisch, Josh Mathews, May Y Liew, Arshdeep Singh, Taryn Lipiner, Autumn Kittilson, Meghan Melberg, Yijia Li, Rebecca F Gilbert, Zahra Reynolds, Surabhi L Iyer, Grace C Chamberlin, Tammy D Vyas, Marcia B Goldberg, Jatin M Vyas, Jonathan Z Li, Jacob E Lemieux, Mark J Siedner, Amy K Barczak

New England Journal of Medicine 2022, June 29 PubMed Read on Journal Site

Virologic Features of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Children

Yonker LM, Boucau J, Regan J, Choudhary MC, Burns MD, Young N, Farkas EJ, Davis JP, Moschovis PP, Bernard Kinane T, Fasano A, Neilan AM, Li JZ, Barczak AK

J Infect Dis . 2021 Dec 1;224(11) PubMed

Duration of viral shedding and culture positivity with postvaccination SARS-CoV-2 delta variant infections

Siedner MJ, Boucau J, Gilbert RF, Uddin R, Luu J, Haneuse S, Vyas T, Reynolds Z, Iyer S, Chamberlin GC, Goldstein RH, North CM, Sacks CA, Regan J, Flynn JP, Choudhary MC, Vyas JM, Barczak AK, Lemieux JE, Li JZ

JCI Insight . 2022 Jan 25;7(2):e155483 PubMed

Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection

Boucau J, Chew KW, Choudhary M, Deo R, Regan J, Flynn JP, Crain CR, Hughes MD, Ritz J, Moser C, Dragavon JA, Javan AC, Nirula A, Klekotka P, Greninger AL, Coombs RW, Fischer WA, Daar ES, Wohl DA, Eron JJ, Currier JS, Smith DM, Li JZ, Barczak AK; ACTIV-2/A5401 Study Team.

Cell Reports Medicine, 7 (3), 19 July 2022 PubMed Read on Journal Site